Udaya Rangaswamy
Director Rondo Therapeutics
Dr. Udaya Rangaswamy is Senior Director of Translational Biology at Rondo Therapeutics. She previously served as a Principal Scientist at Amgen following its acquisition of Teneobio, where she contributed to multiple heme-oncology programs progressing T-cell engager molecules from lead optimization into clinical trials. Her prior postdoctoral work at MedImmune/AstraZeneca focused on oncolytic virotherapy mechanisms, and she holds a PhD in microbiology and molecular genetics from Emory University.
Seminars
Wednesday 24th June 2026
CD28 Targeted Co-Stimulatory Bispecific Antibodies for Treatment of Solid Tumors
2:00 pm
- Discovery of CD28 agonists
- Indication specific development of CD28 targeted bispecific antibodies
- Development of a CD28xNectin-4 bispecific for bladder cancer treatment
